Scale Steps
Big Pharma’s patent cliff sparks biotech deal rush
Big Pharma's $300 billion patent cliff is driving a biotech deal rush as drugmakers scramble to buy new pipelines. Discover the strategy behind the surge.
Read More →
Scale Steps
Real Estate ETFs Beat Market Despite Rising Rates
Real estate ETFs outpace the market despite rising rates. Discover how funds like XLRE and VNQ beat the S&P 500.
Read More →
Scale Steps
Investors flock to ETFs over mutual funds
Investors are shifting from mutual funds to ETFs for better flexibility and lower costs in 2026. Discover why this trend is reshaping wealth management.
Read More →